CRISPR Therapeutics AG has announced that State Street Corporation has acquired a significant stake in the company, holding 4,994,047 shares, which represents 5.2% of its common stock. This move is notable as it underscores the increasing interest in the biological products sector, particularly in innovative gene-editing technologies.
CRISPR Therapeutics AG, incorporated in Zug, Switzerland, operates in the biological products industry, specifically focusing on gene editing and related therapies. The company trades on the Nasdaq under the ticker CRSP and is categorized as a large accelerated filer. Its recent filings include a Schedule 13G, which indicates that State Street Corporation has beneficial ownership of the shares.
The filing, dated November 10, 2026, reveals that State Street Corporation has shared voting power over 4,737,614 shares and shared dispositive power over the total number of shares it owns. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business." This suggests that the acquisition was not intended to influence control of CRISPR Therapeutics.
This acquisition may affect various stakeholders, including investors, analysts, and competitors in the biological products industry. With State Street's significant investment, there may be increased scrutiny on CRISPR Therapeutics' performance and strategic direction. Competitors may need to evaluate their positions in light of this new investment, as it could signal confidence in CRISPR's future prospects.
The filing does not specify what actions might follow this acquisition. However, it is clear that State Street's involvement could have implications for the company's market position and investor relations.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





